Mark Hong


Mark M. Hong joined FPG in 2017 and is responsible for supporting the London team in its research and analysis for value-driven transactions across all Life Science sectors.

Prior to Ferghana Partners, Mark had short-term roles as a Group Risk Analyst at Axis Capital, developing operational budgets and internal valuation models and at Amgen in Regulatory Affairs/CMC (Chemistry, Manufacturing, and Controls), where he supported the submission of regulatory dossiers for Amgen products in the EU, LATAM and EMEA.

Mark is a recent graduate from Imperial College London with an MSci degree in Chemistry with Molecular Physics and was additionally awarded twice on the Natural Sciences Dean’s List for his academic results. His Master’s dissertation focused on developing the next-generation of MRI contrast agents using superparamagnetic iron oxide nanoparticles.